Cargando…

Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies

BACKGROUND: Human papillomavirus (HPV) vaccination of girls will have relatively little effect on HPV-related disease in men who have sex with men (MSM). We determined HPV prevalence and risk factors in MSM to inform the potential effectiveness of vaccinating MSM. METHODS: Cross-sectional study of 5...

Descripción completa

Detalles Bibliográficos
Autores principales: King, E M, Gilson, R, Beddows, S, Soldan, K, Panwar, K, Young, C, Prah, P, Jit, M, Edmunds, W J, Sonnenberg, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453685/
https://www.ncbi.nlm.nih.gov/pubmed/25791874
http://dx.doi.org/10.1038/bjc.2015.90
_version_ 1782374501645811712
author King, E M
Gilson, R
Beddows, S
Soldan, K
Panwar, K
Young, C
Prah, P
Jit, M
Edmunds, W J
Sonnenberg, P
author_facet King, E M
Gilson, R
Beddows, S
Soldan, K
Panwar, K
Young, C
Prah, P
Jit, M
Edmunds, W J
Sonnenberg, P
author_sort King, E M
collection PubMed
description BACKGROUND: Human papillomavirus (HPV) vaccination of girls will have relatively little effect on HPV-related disease in men who have sex with men (MSM). We determined HPV prevalence and risk factors in MSM to inform the potential effectiveness of vaccinating MSM. METHODS: Cross-sectional study of 522 MSM aged 18–40 attending a London sexual health clinic who completed a computer-assisted self-interview. Urine and two swabs (anal and penile/scrotal/perianal) were collected and tested using an in-house Luminex-based HPV genotyping system. RESULTS: Prevalence of DNA of the vaccine-preventable HPV types in ano-genital specimens of men was 87/511 (17.0%), 166/511 (32.5%) and 232/511 (45.4%) for the bivalent (HPV16/18), quadrivalent (HPV6/11/16/18) and nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccine types, respectively. A total of 25.1% had one of the quadrivalent types, and 7.4% had 2+ types. Median age at first anal sex was 19 (IQR 17–23) and at first clinic attendance was 24 (IQR 20–27). The increase in the odds of any HPV infection per year of age was 4.7% (95% CI 1.2–8.4). CONCLUSIONS: On the basis of the current infection status, most MSM, even among a high-risk population attending a sexual health clinic, are not currently infected with the vaccine-type HPV. A targeted vaccination strategy for MSM in the UK could have substantial benefits.
format Online
Article
Text
id pubmed-4453685
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44536852016-04-28 Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies King, E M Gilson, R Beddows, S Soldan, K Panwar, K Young, C Prah, P Jit, M Edmunds, W J Sonnenberg, P Br J Cancer Epidemiology BACKGROUND: Human papillomavirus (HPV) vaccination of girls will have relatively little effect on HPV-related disease in men who have sex with men (MSM). We determined HPV prevalence and risk factors in MSM to inform the potential effectiveness of vaccinating MSM. METHODS: Cross-sectional study of 522 MSM aged 18–40 attending a London sexual health clinic who completed a computer-assisted self-interview. Urine and two swabs (anal and penile/scrotal/perianal) were collected and tested using an in-house Luminex-based HPV genotyping system. RESULTS: Prevalence of DNA of the vaccine-preventable HPV types in ano-genital specimens of men was 87/511 (17.0%), 166/511 (32.5%) and 232/511 (45.4%) for the bivalent (HPV16/18), quadrivalent (HPV6/11/16/18) and nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccine types, respectively. A total of 25.1% had one of the quadrivalent types, and 7.4% had 2+ types. Median age at first anal sex was 19 (IQR 17–23) and at first clinic attendance was 24 (IQR 20–27). The increase in the odds of any HPV infection per year of age was 4.7% (95% CI 1.2–8.4). CONCLUSIONS: On the basis of the current infection status, most MSM, even among a high-risk population attending a sexual health clinic, are not currently infected with the vaccine-type HPV. A targeted vaccination strategy for MSM in the UK could have substantial benefits. Nature Publishing Group 2015-04-28 2015-03-19 /pmc/articles/PMC4453685/ /pubmed/25791874 http://dx.doi.org/10.1038/bjc.2015.90 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Epidemiology
King, E M
Gilson, R
Beddows, S
Soldan, K
Panwar, K
Young, C
Prah, P
Jit, M
Edmunds, W J
Sonnenberg, P
Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title_full Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title_fullStr Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title_full_unstemmed Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title_short Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
title_sort human papillomavirus dna in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453685/
https://www.ncbi.nlm.nih.gov/pubmed/25791874
http://dx.doi.org/10.1038/bjc.2015.90
work_keys_str_mv AT kingem humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT gilsonr humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT beddowss humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT soldank humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT panwark humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT youngc humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT prahp humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT jitm humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT edmundswj humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies
AT sonnenbergp humanpapillomavirusdnainmenwhohavesexwithmentypespecificprevalenceriskfactorsandimplicationsforvaccinationstrategies